Position of the Transparency Council – Vivitrol (extended-release naltrexone)

At its meeting on 12 September 2022 the Transparency Council adopted position No. 88/2022 on on the legitimacy of granting consent for reimbursement of the medicinal product  Vivitrol (extended-release naltrexone) for the indication: mental and behavioural disorders due to alcohol use (F10), including dependence syndrome.

Publication in Public Information Bulletin (BIP)